Clinuvel Pharmaceuticals Ltd (CUVL) · Company profile · Eqvero

Clinuvel Pharmaceuticals Ltd

CUVLNasdaq

Unit: AUD	FY2025	FY2024	FY2023	FY2022
Revenue	86.39 m AUD	81.22 m AUD	72.18 m AUD	60.45 m AUD
Cost of revenue	8.51 m AUD	7.79 m AUD	7.57 m AUD	9.29 m AUD
Research and development expense	7.4 m AUD	2.35 m AUD	1.27 m AUD	1.23 m AUD
Selling, general and administrative expense	32.22 m AUD	28.95 m AUD	24.64 m AUD	19.15 m AUD
Operating profit after depreciation	45.76 m AUD	48.57 m AUD	44.13 m AUD	35.77 m AUD
Operating profit before depreciation	46.9 m AUD	49.65 m AUD	44.87 m AUD	36.49 m AUD
EBIT	45.76 m AUD	48.57 m AUD	44.13 m AUD	35.77 m AUD
EBITDA	46.9 m AUD	49.65 m AUD	44.87 m AUD	36.49 m AUD
Interest expense	4.46 m AUD	4.45 m AUD	3.19 m AUD	2.27 m AUD
Profit before tax	51.55 m AUD	50.68 m AUD	45.58 m AUD	34.32 m AUD
Income tax expense	15.38 m AUD	15.04 m AUD	14.97 m AUD	13.44 m AUD
Income before extraordinary items	36.17 m AUD	35.64 m AUD	30.61 m AUD	20.88 m AUD

Quotes are end-of-day data. Content is for research purposes and is not investment advice.